IN THE NEWS: Frontline Therapy Selection in HCC Hinges on Bleeding Risk and Patient-Specific Factors

OncLive

Hepatocellular carcinoma (HCC) is an advanced-stage liver cancer. Najeeb Al Hallak, M.D., MS, medical oncologist and co-leader of the Gastrointestinal and Neuroendocrine Oncology Multidisciplinary Team at Karmanos, explained factors that should be considered when deciding first-line therapies for HCC patients and gave advice for community oncologists on diagnosing HCC.

Read the article here.

Najeeb Al Hallak, M.D., MS